The DHX58 antibody is a crucial tool in studying the DHX58 protein, also known as LGP2 (Laboratory of Genetics and Physiology 2), which is a member of the retinoic acid-inducible gene I (RIG-I)-like receptor (RLR) family. DHX58 plays a dual role in antiviral innate immunity, acting as both a regulator and a sensor of viral RNA. Unlike its homologs RIG-I and MDA5. LGP2 lacks caspase activation and recruitment domains (CARDs), enabling it to modulate RLR signaling pathways by binding viral RNA or interacting with other RLRs. Antibodies targeting DHX58 are widely used in immunoblotting (Western blot), immunofluorescence, immunoprecipitation, and immunohistochemistry to investigate its expression, localization, and function in immune responses. These antibodies help elucidate mechanisms underlying viral infections (e.g., influenza, SARS-CoV-2), autoimmune disorders, and cancer, where DHX58 dysregulation has been implicated. Researchers often validate DHX58 antibodies using knockout cell lines or tissues to ensure specificity. Commercial DHX58 antibodies are typically raised in rabbits or mice, with monoclonal and polyclonal variants available. Their application has advanced understanding of how DHX58 balances immune activation and tolerance, making them essential in both basic and translational immunology studies.